Characteristics of Current Smokers versus Former Smokers with COPD and Their Associations with Smoking Cessation Within 4.5 Years: Results from COSYCONET

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report gold executive summary. Am J Respir Crit Care Med. 2017;195:557–582. doi:10.1164/rccm.201701-0218PP
   PubMed Web of Science ®Google Scholar
• Agusti A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: gold executive summary. Am J Respir Crit Care Med. 2023;207(7):819–837. doi:10.1164/rccm.202301-0106PP
   PubMed Web of Science ®Google Scholar
• Radaeli A, Nardin M, Azzolina D, Malerba M. Determinants of smoking status in a sample of outpatients afferent to a tertiary referral hospital. Int J Environ Res Public Health. 2019;16(21):4136. doi:10.3390/ijerph16214136
   PubMed Web of Science ®Google Scholar
• Karch A, Vogelmeier C, Welte T, et al. The German COPD cohort COSYCONET: aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016;114:27–37. doi:10.1016/j.rmed.2016.03.008
   PubMed Web of Science ®Google Scholar
• Lederer DJ, Enright PL, Kawut SM, et al. Cigarette smoking is associated with subclinical parenchymal lung disease: the multi-ethnic study of atherosclerosis (mesa)-lung study. Am J Respir Crit Care Med. 2009;180(5):407–414. doi:10.1164/rccm.200812-1966OC
   PubMed Web of Science ®Google Scholar
• Tupper OD, Kjeldgaard P, Løkke A, Ulrik CS. Predictors of COPD in symptomatic smokers and ex-smokers seen in primary care. Chron Respir Dis. 2018;15(4):393–399. doi:10.1177/1479972318761655
   PubMed Web of Science ®Google Scholar
• Zhang PD, Zhang XR, Zhang A, et al. Associations of genetic risk and smoking with incident COPD. Eur Respir J. 2022;59(2):2101320. doi:10.1183/13993003.01320-2021
   PubMed Web of Science ®Google Scholar
• Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374(9691):733–743. doi:10.1016/S0140-6736(09)61303-9
   PubMed Web of Science ®Google Scholar
• Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med. 2022;1010:497–511.
   PubMed Web of Science ®Google Scholar
• Josephs L, Culliford D, Johnson M, Thomas M. Improved outcomes in ex-smokers with COPD: a UK primary care observational cohort study. Eur Respir J. 2017;49(5):1602114. doi:10.1183/13993003.02114-2016
   PubMed Web of Science ®Google Scholar
• Wilson D, Adams R, Appleton S, Ruffin R. Difficulties identifying and targeting COPD and population-attributable risk of smoking for COPD: a population study. Chest. 2005;128128:2035–2042.
   PubMed Web of Science ®Google Scholar
• Wan ES, Fortis S, Regan EA, et al. Investigators CO: longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the copdgene study. Am J Respir Crit Care Med. 2018;198(11):1397–1405. doi:10.1164/rccm.201804-0663OC
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324–1343.
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. report working party standardization of lung function tests, European community for steel and coal official statement of the European respiratory society. Eur Respir J Suppl. 1993;16(Suppl 16):5–40. doi:10.1183/09041950.005s1693
   PubMedGoogle Scholar
• Stanojevic S, Graham BL, Cooper BG, et al. Global lung function initiative twg, global lung function initiative t: official ers technical standards: global lung function initiative reference values for the carbon monoxide transfer factor for caucasians. Eur Respir J. 2017;50(3):1700010. doi:10.1183/13993003.00010-2017
   PubMed Web of Science ®Google Scholar
• Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J. 1999;14(2):270–274. doi:10.1034/j.1399-3003.1999.14b06.x
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT) scores. BMC Pulm Med. 2011;11(42). doi:10.1186/1471-2466-11-42
   PubMedGoogle Scholar
• von Siemens S M, Alter P, Lutter JI, et al. CAT score single item analysis in patients with COPD: results from COSYCONET. Respir Med. 2019;159:105810.
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation the St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–1327.
   Google Scholar
• Wacker ME, Jörres RA, Karch A, et al. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 2016;16(70). doi:10.1186/s12890-016-0238-9
   PubMedGoogle Scholar
• Alter P, Mayerhofer BA, Kahnert K, et al. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2019;14:2163–2172. doi:10.2147/COPD.S209343
   PubMed Web of Science ®Google Scholar
• Alter P, Kahnert K, Trudzinski FC, et al. Disease progression and age as factors underlying multimorbidity in patients with COPD: results from COSYCONET. Int J Chron Obstruct Pulmon Dis. 2022;17:1703–1713.
   PubMed Web of Science ®Google Scholar
• Lucke T, Herrera R, Wacker M, et al. Systematic analysis of self-reported comorbidities in large cohort studies - a novel stepwise approach by evaluation of medication. PLoS One. 2016;11(10):e0163408. doi:10.1371/journal.pone.0163408
   PubMed Web of Science ®Google Scholar
• Houben-Wilke S, Jorres RA, Bals R, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and systemic consequences-comorbidities network study. Am J Respir Crit Care Med. 2017;195(2):189–197. doi:10.1164/rccm.201602-0354OC
   PubMed Web of Science ®Google Scholar
• Lutter JI, Jorres RA, Welte T, et al. Impact of education on COPD severity and all-cause mortality in lifetime never-smokers and longtime ex-smokers: results of the cosyconet cohort. Int J Chron Obstruct Pulmon Dis. 2020;15:2787–2798.
   PubMed Web of Science ®Google Scholar
• Tzani P, Crisafulli E, Nicolini G, et al. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int J Chron Obstruct Pulmon Dis. 2011;6:503–509. doi:10.2147/COPD.S23746
   PubMed Web of Science ®Google Scholar
• Thomas M, Decramer M, O’Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J. 2013;22:101–111.
   PubMedGoogle Scholar
• Soffler MI, Hayes MM, Schwartzstein RM. Respiratory sensations in dynamic hyperinflation physiological and clinical applications. Respir Care. 2017;62:1212–1223.
   PubMed Web of Science ®Google Scholar
• Mayerhofer B, Jorres RA, Lutter JI, et al. Deterioration and mortality risk of COPD patients not fitting into standard gold categories: results of the cosyconet cohort. Respiration. 2021;100(4):308–317. doi:10.1159/000513010
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM, From the global strategy for the diagnosis, management and prevention of COPD, global initiative for Chronic Obstructive Lung Disease (GOLD). Am J Respir Crit Care Med. 2001;163:1256–1276.
   PubMedGoogle Scholar
• Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS, Committee GS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: national heart, lung, and blood institute and world health organization global initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care. 2001;46(8):798–825.
   PubMedGoogle Scholar
• Han MK, Agusti A, Celli BR, et al. From GOLD 0 to Pre-COPD. Am J Respir Crit Care Med. 2021;203(4):414–423. doi:10.1164/rccm.202008-3328PP
   PubMed Web of Science ®Google Scholar
• Alter P, Kahnert K, Trudzinski CF, et al. Clinical factors linked to the type of respiratory medication in COPD: results from the COSYCONET cohort. Ther Adv Respir Dis. 2023;17. doi:10.1177/17534666231208584
   Web of Science ®Google Scholar